Genopole - Réussir ensemble en Biotechnologie

News

Genopole’s Key Figures : click here to consult our interactive document

Consult our 2012 interactive directory of the biotech companies, laboratories and shared-use infrastructure

Bioenergy comes from any fuel that is derived from biomass - recently living organisms or their metabolic byproducts. Biomass can include matter such as cow manure. Unlike other natural resources such as petroleum, coal and nuclear fuels, (...)

63/270 Bioenergy
0/270 Bioethics
24/270 Biomaterials
12/270 Biomedecine
143/270 Biopark
129/270 Biotechnology
6/270 Cell therapy
270/270 Companies
18/270 Environment
23/270 Gene therapy
14/270 Genetics
18/270 Genomics
15/270 Genomics
76/270 Health
39/270 Incubator
90/270 International
59/270 Laboratories
24/270 Nanotechnologies
9/270 Science and society
18/270 Shared-use infrastructure
15/270 Stem cells
59/270 Synthetic biology
14/270 Systemic biology

Signing of an acquisition of a controlling interest in Novagali Pharma by Santen (...)
Issuance of key patents covering new vaccines for VitamFero

Genethon receives approval from the UK medicine (...)

On January 10th 2013, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at (...)
VitamFero signs agreement with Merial to develop (...)

VitamFero has announced a partnership agreement with Merial, the Animal Health Division of Sanofi Group, for developing new vaccines against significant production animal (...)
Progeria: Discovery of a molecular mechanism that (...)

Xavier Nissan’s team I-Stem, at the Institute for Stem Cell Research in the Treatment and Study of Monogenic Diseases (ISTEM-EUVE U861/Inserm/AFM), under the direction of Dr. Marc Peschanski, has discovered a (...)
VitamFero increases its assets with excellent (...)

VitamFero, a biotechnology firm in the Genopole® cluster with a secondary facility in Tours, develops novel veterinary vaccines to prevent certain parasitic diseases. It announces the filing of two new patent (...)
Genethon receives the 2012 Prix Galien France

The 43rd Prix Galien France today recognized Genethon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of “Medicines destined for rare diseases – cell therapy (...)
GLOBAL BIOENERGIES receives the “most innovative (...)

Global Bioenergies, the industrial biology company developing sustainable routes to light olefins, has been selected by EuropaBio, the organization representing more than 1800 European companies, to receive the “most (...)
A SHANGHAI PHYSIOTHERAPY CENTER CHOOSES LOCOMETRIX

The Genopole®-accredited company Centaure Metrix, specialist in the diagnosis and treatment of gait disorders, recently installed their Locometrix® gait diagnostics and therapy system in the Shanghai Sunny (...)
With a promising future, VitamFero improves its (...)

VitamFero, a biotechnology firm in the Genopole® cluster with a secondary base in Tours (Indre & Loire, France) and that develops new vaccines against specific parasitic diseases, announces the addition to its (...)

News

Events